Investment
Features
FeesSafety
Academy
More
Pluang+

Compare 10X Genomics Inc (TXG) vs Unity Software Inc (U) Price & Performance

10X Genomics IncTrade
Unity Software IncTrade

Price performance (Past 24H)

Key statistics

10X Genomics Inc vs Unity Software Inc — how do they compare? 10X Genomics Inc trades at $79.4 (market cap $9.92B), while Unity Software Inc trades at $46.21 (market cap $20.00B). The key difference: Unity Software Inc is far larger — about 2× 10X Genomics Inc's market cap, and Unity Software Inc is trading nearer its 52-week high, 10X Genomics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold 10X Genomics Inc for 92 Days and Unity Software Inc for 50 Days on average.

TXGU
Market Cap
$9.92B$20.00B
Volume
9,372,16612,798,386
Sector
HealthTechnology
52-Week High
$97.74$49.47
52-Week Low
$11.48$17.13
Typical Hold Time
92 Days50 Days
Enterprise Value
$9.44B$19.88B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

10X Genomics Inc

10x Genomics (TXG) trades at $77.28, down 4.19% on the day, amid a bearish technical signal. The company reported revenue of $642.82M in 2025, with a net loss of $43.54M, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights the launch of its Atera spatial biology platform and a patent victory, signaling innovation and market strength. Cash flow from operations improved to $136.05M in 2025, indicating better operational efficiency.

The outlook is cautiously optimistic, with strong product demand and improving margins offering upside potential. However, persistent losses, high valuation multiples, and competitive pressures present significant risks. Analyst consensus is mixed, with a $74.30 price target slightly below the current price, reflecting uncertainty about near-term profitability.

Unity Software Inc

Unity Software (U) trades at $45.89, up 2.09% today, with strong technical momentum and bullish analyst sentiment. The stock shows improving fundamentals with revenue stabilizing around $1.8B-$2.0B and narrowing losses, though profitability remains negative. Recent catalysts include Meta VR Glasses support and positive sector momentum from Accenture's earnings. Technical indicators show the stock trading near resistance at $46 with overbought short-term RSI conditions.

Outlook remains cautiously optimistic with 82% analyst buy ratings and $45.27 consensus target. Key opportunities include VR/AR growth and advertising platform expansion, while risks center on persistent losses, high valuation multiples, and competitive pressures. The stock's current level near analyst targets suggests limited near-term upside without significant earnings improvement.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

TXG
4% Buy96% Sell
Avg holding period · 92 Days
U

No sentiment data available yet.

Top news

Latest headlines on both assets

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG →

About Unity Software Inc

Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.

Read more on U →